These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19679469)

  • 1. Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.
    Takahashi H; Haga Y; Shibata T; Nonoshita K; Sakamoto T; Moriya M; Ohe T; Chiba M; Mitobe Y; Kitazawa H; Iwaasa H; Ishihara A; Ishii Y; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5436-9. PubMed ID: 19679469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
    Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosynthesis and in Vivo Evaluation of Neuropeptide Y5 Receptor (NPY5R) PET Tracers.
    Kumar JS; Walker M; Packiarajan M; Jubian V; Prabhakaran J; Chandrasena G; Pratap M; Parsey RV; Mann JJ
    ACS Chem Neurosci; 2016 May; 7(5):540-5. PubMed ID: 26886507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.
    Kameda M; Ando M; Nakama C; Kobayashi K; Kawamoto H; Ito S; Suzuki T; Tani T; Ozaki S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5124-7. PubMed ID: 19640706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
    J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
    Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
    Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
    Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
    Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PET ligands (+)N-[(11)C]ethyl-3-piperidyl benzilate and (+)N-[(11)C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[(11)C]methyl-3-piperidyl benzilate in the conscious monkey brain.
    Nishiyama S; Tsukada H; Sato K; Kakiuchi T; Ohba H; Harada N; Takahashi K
    Synapse; 2001 Jun; 40(3):159-69. PubMed ID: 11304753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT₇ receptor.
    Lacivita E; Niso M; Hansen HD; Di Pilato P; Herth MM; Lehel S; Ettrup A; Montenegro L; Perrone R; Berardi F; Colabufo NA; Leopoldo M; Knudsen GM
    Bioorg Med Chem; 2014 Mar; 22(5):1736-50. PubMed ID: 24508140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits.
    Johnson AE; Jeppsson F; Sandell J; Wensbo D; Neelissen JA; Juréus A; Ström P; Norman H; Farde L; Svensson SP
    J Neurochem; 2009 Mar; 108(5):1177-86. PubMed ID: 19141073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
    Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and selective small molecule NPY Y5 receptor antagonists.
    Islam I; Dhanoa D; Finn J; Du P; Walker MW; Salon JA; Zhang J; Gluchowski C
    Bioorg Med Chem Lett; 2002 Jul; 12(13):1767-9. PubMed ID: 12067557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.